Table 1.
Comparison of the efficacy profiles (% achievement) of nilotinib,13 dasatinib,19 and bosutinib45 in the 3 registration phase 3 studies compared with imatinib
View large
Comparison of the efficacy profiles (% achievement) of nilotinib,13 dasatinib,19 and bosutinib45 in the 3 registration phase 3 studies compared with imatinib

Nil(300) indicates nilotinib 300 mg; IM, imatinib; DAS, dasatinib; and BOS, bosutinib.

*Median follow-up was 36 months.

†Median follow-up was 24 months.

‡Median follow-up was 18 months.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal